Kidney Disease: Improving Global Outcomes (KDIGO) produces evidence-based global clinical practice guidelines and updated modular guidelines to improve kidney disease care worldwide, adapting to accelerated scientific advances without providing specific trial outcome data.
Kidney Disease: Improving Global Outcomes (KDIGO) develops evidence-based clinical practice guidelines to improve care for people with kidney disease worldwide. KDIGO has produced 17 guidelines across kidney care, and 7 of these have been updated comprehensively at least once. Historically, guidelines were revised in their entirety when novel therapies or treatment paradigms emerged-a process requiring years to complete. To respond more dynamically to accelerated clinical trial results and drug approvals, KDIGO recently adopted a modular update approach for some guidelines. For example, the 2021 Glomerular Diseases Guideline is being updated chapter by chapter, with 4 chapters published since 2024. To support guideline development and promote implementation, additional KDIGO initiatives include Controversies Conferences, which convene global experts to synthesize current knowledge and identify research priorities, and implementation activities such as regional presentations and summits. The pace of scientific advances in kidney disease has never been faster, and KDIGO continues to adapt its programmatic approach to meet the need for trusted, timely guidance.
Grams et al. (Sun,) conducted a other in People with chronic kidney disease worldwide including various subpopulations such as those with hepatitis C, diabetic kidney disease, glomerular diseases, and anemia in CKD. Kidney Disease: Improving Global Outcomes (KDIGO) produces evidence-based global clinical practice guidelines and updated modular guidelines to improve kidney disease care worldwide, adapting to accelerated scientific advances without providing specific trial outcome data.